Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2026)

Acadia Pharmaceuticals' Raw Materials history runs 11 years deep, the most recent figure standing at $74.3 million for Q1 2026.

• On a quarterly basis, Raw Materials fell 2.84% year-over-year to $74.3 million in Q1 2026; TTM through Mar 2026 was $74.3 million, a 2.84% decrease from a year earlier, with the FY2025 full-year figure at $82.8 million, up 18.7% from the prior year.
• Raw Materials eased to $74.3 million in Q1 2026 per ACAD's latest filing, from $82.8 million in the prior quarter.
• Across five years, Raw Materials topped out at $83.7 million in Q2 2025 and bottomed at $5.2 million in Q1 2023.
• The 5-year median for Raw Materials is $42.2 million (2024), against an average of $41.6 million.
• Across the five-year window, Raw Materials declined 16.62% in 2023 and surged 934.36% in 2024, its largest moves.
• Year by year, Raw Materials stood at $5.2 million in 2022, then jumped by 501.34% to $31.3 million in 2023, then surged by 122.73% to $69.7 million in 2024, then rose by 18.7% to $82.8 million in 2025, then decreased by 10.21% to $74.3 million in 2026.
• Per Business Quant, the three latest ACAD Raw Materials figures stand at $74.3 million (Q1 2026), $82.8 million (Q4 2025), and $77.8 million (Q3 2025).